Hopp til hovedinnhold

Premaligne forandringer i cervix

Sist oppdatert: Sist revidert:
Sist revidert av:


Definisjon:
Forstadier til kreft på livmorhalsen, enten i plateepitel eller i kjertelepitel. Årsak er vedvarende infeksjon med et av de onkogene humane papillomavirusene.
Forekomst:
Det diagnostiseres årlig nær 4600 nye behandlingstrengende forstadier til livmorhalskreft i Norge.
Symptomer:
Tilstanden er vanligvis asymptomatisk.
Funn:
Vanligvis normale kliniske funn ved gynekologisk undersøkelse.
Diagnostikk:
Livmorhalsprøve til cytologisk analyse og HPV-test, kolposkopi, biopsi, cervikal abrasio.
Behandling:
Observasjon, konisering eller hysterektomi bestemmes ut ifra histologi, alder og ev. barneønske.
  • Helsedirektoratet (2016). Nasjonalt handlingsprogram med retninglinjer for diagnostikk, behandling og oppfølging av gynekologisk kreft. Oslo; sist faglig oppdatert 28.06.2021
  1. Helsedirektoratet (2016). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av gynekologisk kreft [nettdokument]. Oslo: Helsedirektoratet (sist faglig oppdatert 28. juni 2021, lest 08. mars 2022). www.helsedirektoratet.no  
  2. Kreftregisteret. Kvalitetsmanual for Livmorhalsprogrammet. Oslo, 27.03.2020. www.kreftregisteret.no  
  3. Kreftregisteret. Årsrapport 2019. Screeningaktivitet og resultater fra Livmorhalsprogrammet, Oslo, 2021. www.kreftregisteret.no  
  4. Danckert B, Ferlay J, Engholm G et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Hentet 29.10.2020 www.ancr.nu  
  5. Molden T, Feiring B, Ambur OH et al. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts. Papillomavirus Res 2016; 2: 153-8. pmid:29074174 PubMed  
  6. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011 Dec;121(12):4593-9. Epub 2011 Dec 1. PMID: 22133884 PubMed  
  7. Eide LM, Baasland I. Celleprøvetaking fra cervix - er det så vanskelig?. Gynekologen 2014; 27 (2): 32-4. www.legeforeningen.no  
  8. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590): 890. PMID: 17826171 PubMed  
  9. Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014. pmid:24935346 PubMed  
  10. Jensen KE, Thomsen LT, Schmiedel S. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect 2014. PMID: 24728044 PubMed  
  11. World Health Organization. Comprehensive cervical cancer control. A guide to essential practice. Second edition. Geneva: WHO; 2014. www.who.int  
  12. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. PMID: 16790697 PubMed  
  13. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. PMID: 16835323 PubMed  
  14. Nygård M, Andreassen T, Berland J, et al. 2013. HPV-test i primærscreening mot livmorhalskreft. Kontrollert implementering og evaluering av forbedret helsetjeneste. Oslo, Helsedirektoratet. www.helsedirektoratet.no  
  15. Carozzi FM, Tornesello ML, Burroni E, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2389-2400. pmid: 20826836 PubMed  
  16. Kreftregisteret. Livmorhalsprogrammet. HPV i primærscreening. Sist oppdatert 12.03.2018. Siden besøkt 02.08.2018. www.kreftregisteret.no  
  17. Sørbye SW, Arbyn M, Fismen S, et al. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 2011; 6(10): e26022. pmid:21998748 PubMed  
  18. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013 Nov 1.Lancet. PubMed PMID: 24192252. PubMed  
  19. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months The HPV FOCAL Randomized Clinical Trial. JAMA 2018; 320: 43-52. pmid:29971397 PubMed  
  20. Koliopoulos G, Nyaga VN, Santesso N et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587. DOI: 10.1002/14651858.CD008587.pub2. The Cochrane Library  
  21. Arbyn M, Smith SB, Temin S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018. PMID: 30518635 PubMed  
  22. Polman NJ, Ebisch RMF, Heideman DAM et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol 2019; 20: 229-38. pmid:30658933 PubMed  
  23. Leinonen MK, Schee K, Jonassen CM et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol 2018; 99: 22-30. pmid:29289814 PubMed  
  24. Skjeldestad FE, Hagen B, Hagmar B, Iversen O-E, Juvkam KH, Steen R, Thoresen S, Hareide B. Er cervixcytologisk undersøkelse av unge kvinner mer til skade enn til gagn?. Tidsskr Nor Lægeforen 2007; 127: 1782-5. PubMed  
  25. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010 Aug; 34(8): 1077-87. pmid:20661011 PubMed  
  26. Helsedirektoratet. Nasjonalt handlingsprogram med retninglinjer for gynekologisk kreft. Helsedirektoratet. Oslo, mai 2020. www.helsedirektoratet.no  
  27. Baasland I, Munk AC, Ernø LE et al. Premaligne og maligne forandringer i cervix i graviditet. Veileder i fødselshjelp. Norsk gynekologisk forening. Oslo, 2020. Siden besøkt 02.11.2020 www.legeforeningen.no  
  28. Nordland K, Skjeldestad FE, Hagen B. Behandling av cervikal intraepitelial neoplasi før og etter innføring av laserkonisering. Tidsskr Nor Lægeforen 2005; 125: 167-9. PubMed  
  29. Gynekologisk kreft - handlingsprogram. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av gynekologisk kreft. IS-2462. Utgitt 20.09.16. helsedirektoratet.no  
  30. Vaksinasjonsveilederen: HPV-vaksine - veileder for helsepersonell. Folkehelseinstituttet. Oppdatert: 17.06.2020. www.fhi.no  
  31. Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2020 Aug 1;147(3):641-647. PMID: 31648368.
  32. Tainio K, Athanasiou A, Tikkinen KAO et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360 :k499. PMID: 29487049 PubMed  
  33. Koeneman MM, van Lint FHM, van Kuijk SMJ et al. A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. Hum Pathol 2017; 59: 62-9. pmid:27697590 PubMed  
  34. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S. Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstet Gynecol. 2016;128(6):1265-1273. PMID: 27824756 PubMed  
  35. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633. Published 2016 Jul 28. PMID: 27469988 PubMed  
  36. Kyrgiou M, Athanasiou A, Kalliala IEJ et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD012847. DOI: 10.1002/14651858.CD012847. The Cochrane Library  
  37. Strander B, Andersson-Ellstrøm A, Milsom I,Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: a population based cohort study. BMJ 2007; 335-1077-83. PMID: 17959735 PubMed  
  38. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol Oncol 2013 Aug;130(2):264-8. doi:10.1016/j.ygyno.2013.04.050. PMID: 23623831 PubMed  
  39. Grimm C, Polterauer S, Natter C, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial. Obstet Gynecol 2012; 120(1):152-9. PMID: 22914404 PubMed  
  40. Tao XH, Guan Y, Shao D, et al. . Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: a systemic review. Photodiagnosis Photodyn Ther 2014 Jun; 11(2): 104-12. pmid:24631593 PubMed  
  41. International Agency for Research on Cancer/World Health Organization. IARC Handbooks of Cancer Prevention: Cervix cancer screening. Volume 10. Lyon: IARC Press, 2005. publications.iarc.fr  
  42. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.. Lancet 2007; 370 (9599): 1609. pmid:17993361 PubMed  
  43. Sørbye SW, Suhrke P, Revå BW, et al. Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway. BMC Clin Pathol 2017 Aug 29; 17:18: eCollection 2017. pmid:28860942 PubMed  
  44. Andreassen T, Vogt C. Screening for livmorhalskreft i endring. Tidsskrift for Den norske legeforening 2014; 11: 1122-3. doi:10.4045/tidsskr.14.0240 DOI  
  45. Dillner J, Rebolj M, Birembaut P, et al. Long trem predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754. pmid: 18852164 PubMed  
  46. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-9. pmid:17471427 PubMed  
  47. Rodríguez AC, Schiffman M, Herrero R, et al. Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. J Natl Cancer Inst 2008; 100 (7): 513-7. PMID: 18364507 PubMed  
  48. Kreftregisteret. Årsrapport 2017-18. Resultater og forbedringstiltak fra Livmorhalsprogrammet, Oslo, mai 2020. www.kreftregisteret.no  
  49. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020, www.kreftregisteret.no. www.kreftregisteret.no  
  • Ameli Tropé, overlege dr. med, Kreftregisteret
  • Silje Folven Barlindhaug, spesialist i allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Finn Egil Skjeldestad, lege og professor, Institutt for samfunnsmedisinske fag UiT Norges arktiske universitet, Tromsø
  • Sveinung Sørbye, overlege PhD, avdeling for klinisk patologi, Universitetssykehuset i Nord-Norge, Tromsø